NPPB and hydrops fetalis: However, one should keep in mind that in the STRONG-HF trial, only those patients could be randomised for whom eGFR ≥ 30 mL/min/1.73 m2, NT-proBNP at screening >2500 pg/mL and at randomisation >1500 pg/mL with a >10% decrease between screening and before randomisation, serum potassium level ≤ 5.0 mmol/L, systolic blood pressure ≥ 100 mmHg and heart rate ≥ 60 min−1 [38].